Home Category Region Publishers About Us Contact Us
Home > Market Research Report > Pharmaceutical > Infectious Disease > An Evaluation of Product Usage for Molecular Testing within Infectious Diseases
Category
Pharmaceutical (4989)
Bone Disease Treatment (46)
Cancer (883)
Diabetes (159)
Drug Delivery System (184)
Drug Discovery (1403)
Generic Drugs (128)
Infectious Disease (406)
Mental Disease (98)
Neurodegenerative Disease (180)
Obesity Treatment (49)
OTC Drug (149)
Pharmaceutical Companies (562)
Prescription Drugs (120)
Regulation (122)
Vaccines (178)
Veterinary Medicine (28)
Market Research Report

An Evaluation of Product Usage for Molecular Testing within Infectious Diseases

Published by HBS Consulting
Published September, 2004 Product code 21594
Content info  
Price
Not Available

This publication has been discontinued on July 19, 2011.

Introduction

The new report by HBS Consulting examines the reality of 221 laboratories and hospitals in 11 European countries and provides you with following information:

Molecular Tests

  • Description of laboratory landscape per country
  • the number of performed tests for 47 pathogens
  • which products, technologies and manufacturers are used per pathogen . determine current laboratory equipment that is used for microbiology testing
  • Unmet needs
  • which tests, technologies and products show the most promising market opportunities in the short to medium term
  • market potential in volume per test, technology and country
  • regulatory issues per country (legislation, reimbursement

Product Value Proposition

The study will allow the owner of the information to:

  • Assess current market realities in terms of currently performed tests / Used technologies at an unparalleled level of segmentation
  • Get detailed knowledge on suppliers of molecular test kits / equipment, (by segmentation criteria)
  • Reflect the current situation not only at a specific point in time, but monitor trends over a period of time (both in terms of market participants as well as system types)
  • Model market and own sales forecasts on system types based on investment plans of customers
  • Reflect the expected behaviour of buyers, not just the expectations of sellers; but by the motivations of buyers.
  • Model market forecasts on associated product lines (e.g. PCR Cycler, NAT related devices) based on procedure data
  • Make decisions regarding the market entry/marketing strategy

Respondents have been chosen randomly in order to guarantee that the respondents reflect the real market situation. However the definition of the project required the focus on such institutions that perform molecular testing particularly.

Table of Contents(Germany)

1.1 Project Objectives5

1.2 Definitions7

1.3 German HealthCareSystem and Reimbursement9

1.4 German Laboratory Landscape14

1.5 RespondentPopulation Germany15

2.1 Sexual TransmittedDiseases(STD)17

ChlamydiaTrachomatis19
Neisseria21
HIV22
HCV23
Group B Streptococcus24
HSV25

2.2 Mycobacteria25

MycobacteriaTuberculosis28
MycobacteriaAvium29
Mycobacteria?NA Purification31

2.3 AtypicalPneumoniae32

Bordetella33
Legionella33
Chlamydiasp.34
MycoplasmaPneumoniae35

2.4 Cytomegalovirus(CMV)36

CMV ?Qualitative Tests37
CMV ?Quantitative Tests37

2.5. ViralMeningitis38HSV 1 & 239

Enterovirus41
West NileVirus (WNV)41
Epstein BarrVirus (EBV)42
VZV43

2.6 RespiratoryViruses44

SARS45
Adenovirus46
Influenza A46
Influenza A&B47
RSV48
Parainfluenza48

2.7 HPV49

2.8 ChronicMeningitis50

2.9 BacterialMeningitis53

NeisseriaMeningitis54
HaemophilusInfluenza54
Pneumococcae55
Listeria55
Enterobacteria56

2.10 Tick Born Encephalitis56

2.11 AntibioticResistantBacteria59

2.12 Candida61

3. Equipment & Purchase63

3.1 CurrentInstallations& Financingof Laboratory Equipment63

Cobas Amplicor, Roche64
Light Cycler, Roche64
ABI PRISM, AppliedBiosystems64
RotorGene, CorbettResearch64
OtherCycler65
OtherDevices/Manufacturers66

3.2 Budget Resources67

3.3 WhoisInvolvedin PurchasingDecisions70

3.4 Howdo LaboratoriesPurchase72

3.5 CriteriaInfluencea PurchasingDecision74

3.6 WhatareLaboratoriesWillingto PayforNew Tests? 75

4. Market Sizesand Market Shares 76

4.1 Market VolumesforSelectedPathogens76

STD77
MycobacteriaTuberculosis78
AtypicalPneumonia78
CMV79
ViralMeningitis80
RespiratoryViruses81
HPV82
MRSA82

4.2 Market Shares83

5. Market Trends 85

5.1 Problems withMolecularDiagnostics85

5.2 ExpectedGrowth per Segment86

6.3 OtherGrowth Areas90

5.4 Drivers forMolecularDiagnostics91

5.5 RestraintsforMolecularDiagnostics92

6. PoliticalInfluences93

6.1 Changesof ReimbursementPolicy93

6.2 Influenceof the EU IVD Act94

Back to Top